118 related articles for article (PubMed ID: 15718311)
1. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.
Rimawi MF; Shetty PB; Weiss HL; Schiff R; Osborne CK; Chamness GC; Elledge RM
Cancer; 2010 Mar; 116(5):1234-42. PubMed ID: 20082448
[TBL] [Abstract][Full Text] [Related]
3. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
[TBL] [Abstract][Full Text] [Related]
4. Endosomal protein expression of γ1-adaptin is associated with tumor growth activity and relapse-free survival in breast cancer.
Hoshi N; Uemura T; Tachibana K; Abe S; Murakami-Nishimagi Y; Okano M; Noda M; Saito K; Kono K; Ohtake T; Waguri S
Breast Cancer; 2024 Mar; 31(2):305-316. PubMed ID: 38265632
[TBL] [Abstract][Full Text] [Related]
5. HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies.
Loeffler E; Ancel J; Dalstein V; Deslée G; Polette M; Nawrocki-Raby B
Life (Basel); 2023 Dec; 14(1):. PubMed ID: 38255679
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and Somatostatin Receptors in Tumour Biology.
Kumar U
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203605
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Trastuzumab.
Vivekanandhan S; Knutson KL
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291900
[TBL] [Abstract][Full Text] [Related]
8. Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients.
Ramić S; Paić F; Smajlbegović V; Perić Balja M; Hiršl L; Marton I; Knežević F
Croat Med J; 2022 Apr; 63(2):126-140. PubMed ID: 35505646
[TBL] [Abstract][Full Text] [Related]
9. A seven-lncRNA signature for predicting prognosis in breast carcinoma.
Xu M; Chen Z; Lin B; Zhang S; Qu J
Transl Cancer Res; 2021 Sep; 10(9):4033-4046. PubMed ID: 35116701
[TBL] [Abstract][Full Text] [Related]
10. Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy.
Peckys DB; Gaa D; de Jonge N
Cells; 2021 Nov; 10(11):. PubMed ID: 34831465
[TBL] [Abstract][Full Text] [Related]
11. Laser Capture Proteomics: spatial tissue molecular profiling from the bench to personalized medicine.
Liotta LA; Pappalardo PA; Carpino A; Haymond A; Howard M; Espina V; Wulfkuhle J; Petricoin E
Expert Rev Proteomics; 2021 Oct; 18(10):845-861. PubMed ID: 34607525
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer.
Kavarthapu R; Anbazhagan R; Dufau ML
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572912
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers.
Beyaz H; Uludag H; Kavaz D; Rizaner N
Adv Exp Med Biol; 2021; 1347():163-181. PubMed ID: 34287795
[TBL] [Abstract][Full Text] [Related]
14. HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line.
Lee HJ; Shin S; Kang J; Han KC; Kim YH; Bae JW; Park KH
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32942617
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
Wulfkuhle JD; Yau C; Wolf DM; Vis DJ; Gallagher RI; Brown-Swigart L; Hirst G; Voest EE; DeMichele A; Hylton N; Symmans F; Yee D; Esserman L; Berry D; Liu M; Park JW; Wessels LFA; Van't Veer L; Petricoin EF
JCO Precis Oncol; 2018; 2():. PubMed ID: 32914002
[TBL] [Abstract][Full Text] [Related]
16. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance.
Zhang Y
Pharmacol Ther; 2021 Feb; 218():107677. PubMed ID: 32898548
[TBL] [Abstract][Full Text] [Related]
17. Sulfation modulates the targeting properties of hyaluronic acid to P-selectin and CD44.
Bhattacharya DS; Svechkarev D; Bapat A; Patil P; Hollingsworth MA; Mohs AM
ACS Biomater Sci Eng; 2020 Jun; 6(6):3585-3598. PubMed ID: 32617404
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
Burguin A; Furrer D; Ouellette G; Jacob S; Diorio C; Durocher F
PLoS One; 2020; 15(6):e0234991. PubMed ID: 32584853
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Modeling of Reoxygenation Effects on mRNA and Protein Levels in Hypoxic Tumor Cells upon Entry into the Bloodstream.
Bartkowiak K; Koch C; Gärtner S; Andreas A; Gorges TM; Pantel K
Cells; 2020 May; 9(5):. PubMed ID: 32466213
[TBL] [Abstract][Full Text] [Related]
20. New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified.
MacNeil IA; Burns DJ; Rich BE; Soltani SM; Kharbush S; Osterhaus NG; Sullivan BF; Hawkins DM; Pietruska JR; Laing LG
J Cancer Res Clin Oncol; 2020 Mar; 146(3):605-619. PubMed ID: 32036454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
